日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Transcriptional profiling clarifies a program of enzalutamide extreme non-response in lethal prostate cancer.

转录组分析揭示了致命性前列腺癌中恩扎卢胺极度无反应的机制

Kumaraswamy Anbarasu, Hu Ya-Mei, Yates Joel A, Zhang Chao, Rodansky Eva, Khokhani Dhruv, Flores Diana, Duan Zhi, Zhang Yi, Tabatabaei Shaadi, Slottke Rachel, Ye Shangyuan, Lara Primo, Foye Adam, Ryan Charles J, Quigley David A, Huang Jiaoti, Aggarwal Rahul, Reiter Robert E, Wicha Max S, Beer Tomasz M, Rettig Matthew, Gleave Martin, Evans Christopher P, Witte Owen N, Stuart Joshua M, Thomas George V, Feng Felix Y, Small Eric J, Xia Zheng, Alumkal Joshi J

Composition of gastrointestinal microbiota in association with treatment response in individuals with metastatic castrate resistant prostate cancer progressing on enzalutamide and initiating treatment with anti-PD-1 (pembrolizumab)

转移性去势抵抗性前列腺癌患者在接受恩杂鲁胺治疗后病情出现进展,并开始接受抗 PD-1(派姆单抗)治疗时,其胃肠道菌群组成与治疗反应的关系

Lauren B Peiffer, James R White, Carli B Jones, Rachel E Slottke, Sarah E Ernst, Amy E Moran, Julie N Graff, Karen S Sfanos

A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone

一项针对接受恩扎卢胺单药治疗后病情进展的转移性去势抵抗性前列腺癌男性患者的II期单臂研究,评估帕博利珠单抗联合恩扎卢胺的疗效。

Graff, Julie N; Beer, Tomasz M; Alumkal, Joshi J; Slottke, Rachel E; Redmond, William L; Thomas, George V; Thompson, Reid F; Wood, Mary A; Koguchi, Yoshinobu; Chen, Yiyi; Latour, Emile; Bergan, Raymond C; Drake, Charles G; Moran, Amy E

Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer

PI3激酶抑制剂布帕利西布(BKM-120)联合或不联合恩扎卢胺治疗转移性去势抵抗性前列腺癌男性患者的II期临床试验

Armstrong, Andrew J; Halabi, Susan; Healy, Patrick; Alumkal, Joshi J; Winters, Carolyn; Kephart, Julie; Bitting, Rhonda L; Hobbs, Carey; Soleau, Colleen F; Beer, Tomasz M; Slottke, Rachel; Mundy, Kelly; Yu, Evan Y; George, Daniel J

Androgen receptor amplification is concordant between circulating tumor cells and biopsies from men undergoing treatment for metastatic castration resistant prostate cancer

接受转移性去势抵抗性前列腺癌治疗的男性的循环肿瘤细胞和活检样本中的雄激素受体扩增一致

Jennifer Podolak, Kristi Eilers, Timothy Newby, Rachel Slottke, Erin Tucker, Susan B Olson, Hui-Wen Lue, Jack Youngren, Rahul Aggarwal, Eric J Small, Julie N Graff, Joshi J Alumkal, Tomasz M Beer, George V Thomas

Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer

恩杂鲁胺耐药前列腺癌中抗 PD-1 活性的早期证据

Julie N Graff, Joshi J Alumkal, Charles G Drake, George V Thomas, William L Redmond, Mohammad Farhad, Jeremy P Cetnar, Frederick S Ey, Raymond C Bergan, Rachel Slottke, Tomasz M Beer

A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer

富含萝卜硫素的西兰花芽提取物对复发性前列腺癌男性患者的 II 期研究

Joshi J Alumkal, Rachel Slottke, Jacob Schwartzman, Ganesh Cherala, Myrna Munar, Julie N Graff, Tomasz M Beer, Christopher W Ryan, Dennis R Koop, Angela Gibbs, Lina Gao, Jason F Flamiatos, Erin Tucker, Richard Kleinschmidt, Motomi Mori